Drug profile

The FDA adverse-event record for Ursodiol

691 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Ursodiol. See the species affected, top reactions, and outcomes below.

691
adverse-event reports
15.5%
death-coded share
Dog
most-reported species
138
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
691
Total Reports
107
Deaths Reported
15.5%
Death Rate

Active Ingredients

Ursodiol

Administration Routes

OralUnknownOther

Species Affected

Dog 653
Cat 38

Most Affected Breeds

Retriever - Labrador 75
Crossbred Canine/dog 41
Chihuahua 37
Shih Tzu 26
Domestic Shorthair 26
Beagle 25
Schnauzer - Miniature 22
Sheepdog - Shetland 20
Spitz - German Pomeranian 19
Dog (unknown) 19

Most Reported Reactions

Vomiting 138
Elevated alanine aminotransferase (ALT) 116
Diarrhoea 101
Lethargy (see also Central nervous system depression in 'Neurological') 99
Elevated serum alkaline phosphatase (SAP) 88
Decreased appetite 80
Death by euthanasia 77
Weight loss 65
Elevated total bilirubin 63
Anorexia 61
Abnormal ultrasound finding 58
Other abnormal test result NOS 54

Outcome Breakdown

Ongoing
225 (32.6%)
Outcome Unknown
214 (31.0%)
Recovered/Normal
132 (19.1%)
Euthanized
77 (11.2%)
Died
30 (4.3%)
Recovered with Sequela
12 (1.7%)

Ursodiol Adverse Event Insights

691 reports name Ursodiol; 107 recorded a death outcome (15.5% of reported events, not a population-level mortality rate). Active ingredient: Ursodiol. Administration routes: Oral, Unknown, Other.

By species: Dog (653 reports), Cat (38 reports). By breed: Retriever - Labrador (75), Crossbred Canine/dog (41), Chihuahua (37).

Leading clinical signs: Vomiting (138), Elevated alanine aminotransferase (ALT) (116), Diarrhoea (101), Lethargy (see also Central nervous system depression in 'Neurological') (99). Outcome, 690 coded reports: Ongoing leads at 32.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.